Sutro Biopharmaincis A Clinical Stage Biotechnology Company Based In South San Franciscocaliforniait Specializes In The Discovery And Development Of Engineered Cancer Therapeuticsthe Company Is Publicly Traded On Nasdaq Under The Symbol Stro And Utilizes Its Proprietary Cell Free Xpresscfaplatform To Create Innovative Therapies Aimed At Improving Patient Outcomes Sutro Focuses On Advancing Antibody Drug Conjugatesadcsand Other Targeted Cancer Treatmentsits Technology Allows For Rapid Design And Optimization Of Biologicsincluding Adcs With Dual Payload Capabilitiesthe Company Is Currently Developing Luveltamab Tazevibulinluvelta A Registrational Stage Adc Targeting Folate Receptor Alphawhich Is In Clinical Trials For Ovarian And Endometrial Cancerssutro Also Engages In Partnerships With Pharmaceutical Companies To Enhance The Development And Commercialization Of Its Therapeutics
